TITLE

UK NICE far from perfect, says health economist

PUB. DATE
December 2006
SOURCE
PharmacoEconomics & Outcomes News;12/2/2006, Issue 517, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
A reprint of the article "Economic Evaluation and Decision Making in the UK," by Martin J. Buxton in a 2006 issue of "PharmacoEconomics" is presented. It contends that there are significant problems in the decision-making process of Great Britain's National Institute for Health and Clinical Excellence (NICE). It criticizes the incremental cost-effectiveness ratio threshold of NICE. It explains the difficulty or unwillingness of several local health services to fully implement NICE guidance.
ACCESSION #
23577490

 

Related Articles

  • NICE rejoinder. Harris, John // Journal of Medical Ethics;Aug2007, Vol. 33 Issue 8, p467 

    The article discusses the cost effectiveness of health benefits offered in Great Britain. To have an idea on the gains made and the gains forgone, NICE should know accurately which gains have foregone. According to Claxton and Culyer, neither NICE or any decision making entity can know which NHS...

  • Commentary: Clinical freedom is dead and no one need regret its passing. Maynard, Alan // International Journal of Epidemiology;Aug2011, Vol. 40 Issue 4, p858 

    No abstract available.

  • News Focus--How NICE makes decisions on QOF. Moberly, Tom // Independent Nurse;1/15/2010, p1 

    Information on the meeting of National Institute for Health and Clinical Excellence (NICE) Independent Quality and Outcomes Framework (QOF) Review Committee, which was conducted in Great Britain, is presented. Topics including recommendations for changes to QOF, referral to a type-2 diabetes...

  • Evaluation of genotyping methods and the relative cost of pharmacogenomics. DE MONACO, A.; BERRETTA, M.; PUGLIESE, S.; VALENTE, D.; CIAFFARAFA, S.; DI FRANCIA, R. // European Review for Medical & Pharmacological Sciences;Jul2014, Vol. 18 Issue 14, p2084 

    Recently, several methods to assess the quality of cost-effectiveness, cost-utility and cost-benefit in the pharmacogenomic field have become available. A relevant example is the National Institute for Health and Clinical Excellence (NICE). NICE forms a diverse clinical Advisory committee, which...

  • Parliamentary report makes NICE recommendations.  // PharmacoEconomics & Outcomes News;1/26/2008, Issue 545, p2 

    The article reports the release of a British House of Commons health select committee report on the performance of National Institute for Health and Clinical Excellence (NICE) in January 2008. The report contains recommendations on how NICE can improve the transparency of its decision-making...

  • Health outcomes in economic evaluation: who should value health? Stamuli, Eugena // British Medical Bulletin;Mar2011, Vol. 97 Issue 1, p197 

    The valuation of health states is an integral part of economic evaluation studies. The source of these valuations (general public vs. patients) is surrounded by controversy. Health state values generated by the general public are often different compared with those of patients. General public...

  • NICE: alone in Europe but not the world. Gillies, Malcolm B. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/21/2009, p429 

    No abstract available.

  • NICE is to confer on taking more account of patients' views. White, Caroline // BMJ: British Medical Journal (International Edition);10/25/2008, Vol. 337 Issue 7676, p951 

    The article reports that the British National Institute for Health and Clinical Excellence will invite patients and health economists to express their views on the factors used in determining which drugs to recommend for use in Great Britain's National Health Service. Views regarding the use of...

  • Valuing health at the end of life: an empirical study of public preferences. Shah, Koonal; Tsuchiya, Aki; Wailoo, Allan // European Journal of Health Economics;May2014, Vol. 15 Issue 4, p389 

    In 2009, the National Institute for Health and Clinical Excellence (NICE) issued supplementary advice to its Appraisal Committees to be taken into account when appraising life-extending, 'end-of-life' treatments. This indicated that if certain criteria are met, it may be appropriate to recommend...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics